Depressive DisorderNCT07807072
iACT & iTBS for Sleep Quality in Depressed Adolescents
A study testing Internet-Delivered Acceptance and Commitment Therapy and Intermittent Theta Burst Stimulation in people with Depressive Disorder and Sleep Disturbance, run by Central China Normal University at 1 site in China.
Trial summary
This study evaluated whether combining an internet-delivered Acceptance and Commitment Therapy program with intermittent theta burst stimulation improves subjective sleep quality in adolescents with depressive disorders and sleep disturbances. Read more about this study
- Who is it for?
- Ages 11 to 19 years
- Conditions the study is for
- Depressive Disorder, Sleep Disturbance
- What is being tested?
- Internet-Delivered Acceptance and Commitment Therapy and Intermittent Theta Burst Stimulation
- Type of treatment
- Medical device, Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 160 participants
- Where
- 1 siteChina
- Study dates
- 1 Aug 2023to 30 Jan 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 11 to 19 years
- All sexes
- No healthy volunteers
- Child, Adult
Who may be able to join
- Age 11 to 19 years.
- A primary depressive disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), confirmed by independent evaluations conducted by two board-certified psychiatrists using semistructured clinical interviews. Any discrepancy was adjudicated by a senior psychiatrist.
- Hamilton Depression Rating Scale, 17-item version (HAMD-17) score of at least 8.
- Current subjective sleep disturbance, including difficulty initiating sleep, frequent nighttime awakenings, or nonrestorative sleep, confirmed during the diagnostic interview.
- Either no antidepressant medication or stable antidepressant pharmacotherapy for at least 2 weeks before enrollment.
- No concurrent systematic psychological or physical treatment during the study.
- Right-handedness.
- Written informed consent from a parent or legal guardian and written assent from the adolescent participant.
Who cannot join
- History of epilepsy, major neurological disorder, or any contraindication to transcranial magnetic stimulation, including relevant metal implants.
- Acute suicide risk requiring immediate clinical intervention.
- Substance use disorder within the previous year.
- Severe somatic illness that could interfere with study participation or outcome assessment.
- Current use of targeted hypnotic or sedative medication.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Internet-Delivered ACT and Intermittent Theta Burst Stimulation for Subjective Sleep Quality in Depressed Adolescents: A Randomized Controlled Trial
This study evaluated whether combining an internet-delivered Acceptance and Commitment Therapy program with intermittent theta burst stimulation improves subjective sleep quality in adolescents with depressive disorders and sleep disturbances. Acceptance and Commitment Therapy is a psychological treatment that teaches skills for accepting difficult thoughts and feelings, reducing unhelpful struggle with them, and taking actions consistent with personal values. Intermittent theta burst stimulation is a brief, noninvasive form of brain stimulation delivered over the left dorsolateral prefrontal cortex.
A total of 152 adolescents aged 11 to 19 years were randomly assigned to one of four groups: combined internet-delivered Acceptance and Commitment Therapy plus intermittent theta burst stimulation, internet-delivered Acceptance and Commitment Therapy alone, intermittent theta burst stimulation alone, or a waitlist control group. Treatment was provided over 12 consecutive days. Participants completed assessments before treatment, immediately after treatment, and 30 days later.
The study was registered retrospectively after participant recruitment and data collection had begun. The primary outcome was subjective sleep quality, measured with the Pittsburgh Sleep Quality Index. Secondary outcomes were depressive symptom severity and psychological flexibility. The study also assessed treatment exposure and adverse events, including headache or scalp discomfort associated with brain stimulation.
Read the detailed description
This was a four-arm, parallel-group, randomized controlled superiority trial conducted in the outpatient department of a psychiatric hospital in Anhui Mental Health Center. The study was retrospectively registered on the Open Science Framework in May 2024. The study protocol was approved by the institutional review board (Approval No.: CCNU-IRB-202306017b). Written informed consent was obtained from a parent or legal guardian, and written assent was obtained from each adolescent participant.
Participants were recruited by convenience sampling between August 2023 and January 2024. Eligible participants were 11 to 19 years old; had a primary DSM-5 depressive disorder confirmed by independent evaluations from two board-certified psychiatrists using semistructured clinical interviews; had a Hamilton Depression Rating Scale, 17-item version (HAMD-17) score of at least 8; and reported a concurrent subjective sleep disturbance, such as difficulty initiating sleep, frequent nighttime awakenings, or nonrestorative sleep. Participants were required either to be receiving stable antidepressant pharmacotherapy for at least 2 weeks or to be taking no antidepressant medication. Participants could not be receiving another systematic psychological or physical treatment and were required to be right-handed.
Participants were excluded for a history of epilepsy, a major neurological disorder, a contraindication to transcranial magnetic stimulation, acute suicide risk, a substance use disorder within the preceding year, severe somatic illness, or current use of targeted hypnotic or sedative medication.
Participants were randomly assigned in a 1:1:1:1 ratio using a computer-generated permuted-block randomization sequence. Allocation was managed by personnel independent of outcome assessment. Independent HAMD-17 raters were masked to treatment assignment. Participants and intervention-delivery personnel were not masked because the treatment formats and waitlist condition were distinguishable. Self-report outcome measures were completed by participants.
The internet-delivered Acceptance and Commitment Therapy program was provided through a custom-developed WeChat mini-program. The program included an introduction, six sequential treatment modules, and a concluding session. The content was delivered over 12 days and covered psychoeducation, acceptance, cognitive defusion, mindfulness, values clarification, and values-consistent action. The modules were unlocked on days 1, 3, 5, 7, 9, and 11, with approximately 15 minutes required for each component. The total planned exposure was approximately 120 minutes. All modules were completed on site during daily hospital visits. Online records and staff monitoring were used to document module completion and practice activities. A crisis hotline was embedded in the program.
Intermittent theta burst stimulation was administered once daily for 12 consecutive days using a Magstim Rapid2 stimulator with a 70-mm figure-of-eight coil. The individualized stimulation target was located over the left dorsolateral prefrontal cortex using integrated neuronavigation. Resting motor threshold was measured before treatment. Each session delivered 1,800 pulses in three 600-pulse blocks. Stimulation consisted of three-pulse 50-Hz bursts repeated at 5 Hz, delivered in 2-second trains separated by 8-second intervals. Stimulation intensity was 100% of the participant's resting motor threshold.
Participants in the combined group received both interventions. On days when a new Acceptance and Commitment Therapy module was available, theta burst stimulation was delivered first and was immediately followed by the module. On intervening days, participants received theta burst stimulation only. Participants in the internet-delivered therapy-only group followed the module schedule without theta burst stimulation. Participants in the stimulation-only group received theta burst stimulation without the therapy program during the intervention period. Participants assigned to the waitlist received no targeted intervention during the 42-day study period and completed assessments on the same schedule as the active-treatment groups. Access to the internet-delivered Acceptance and Commitment Therapy program was offered to participants in the waitlist and stimulation-only groups after the final follow-up assessment.
Assessments were conducted at baseline, immediately after the 12-day intervention, and at a 30-day follow-up. The primary outcome was subjective sleep quality, measured with the 19-item Pittsburgh Sleep Quality Index, with total scores ranging from 0 to 21 and higher scores indicating worse sleep quality. Secondary outcomes were depressive symptom severity, measured with the 17-item Hamilton Depression Rating Scale, and psychological flexibility, measured with the 12-item flexibility subscale of the Multidimensional Psychological Flexibility Inventory-24. Demographic information, including age, gender, school grade, only-child status, and urban or rural residence, was collected at baseline.
Adverse events and unintended effects were assessed through spontaneous participant reports during and after the intervention procedures. Examples included headache and scalp discomfort associated with intermittent theta burst stimulation.
The primary analyses examined changes from baseline to post-treatment and follow-up across the four groups. Repeated-measures models were used to account for the correlation among observations from the same participant. The main comparisons evaluated the combined intervention against the waitlist and against each monotherapy, as well as each monotherapy against the waitlist. Analyses adjusted for age, gender, and only-child status. Additional analyses examined clinical response in sleep quality, the robustness of findings under alternative model specifications, and whether the combined intervention showed evidence of greater-than-additive change relative to the two monotherapies. All 152 participants completed the three scheduled assessments.
This study was registered retrospectively after participant recruitment and data collection had begun.
- Conditions
- Depressive Disorder, Sleep Disturbance
- Being tested
- Internet-Delivered Acceptance and Commitment Therapy, Intermittent Theta Burst Stimulation
- Keywords
- Subjective sleep quality, depression, internet-delivered Acceptance and Commitment Therapy, intermittent Theta Burst Stimulation, psychological flexibility
- Medical subject headings
- Depressive Disorder, Parasomnias, Depression
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Internet-Delivered Acceptance and Commitment TherapyBehavioural
Also called iACT, Internet-delivered ACT
Participants received a self-guided internet-delivered Acceptance and Commitment Therapy program through a custom-developed WeChat mini-program over 12 consecutive days. The program included an introduction, six sequential treatment modules, and a concluding session. Modules were unlocked on days 1, 3, 5, 7, 9, and 11, and each component required approximately 15 minutes, for a total planned exposure of approximately 120 minutes. Content was based on the ACT hexaflex model and included psychoeducation, acceptance, cognitive defusion, mindfulness, values clarification, and values-consistent action. Participants completed the modules on site during daily hospital visits. Module completion and practice activities were monitored through the mini-program and by research staff. A crisis hotline was embedded in the program.
Intermittent Theta Burst StimulationDevice
Also called iTBS, Intermittent TBS
Intermittent theta burst stimulation was administered once daily for 12 consecutive days using a Magstim Rapid2 stimulator with a 70-mm figure-of-eight coil. The individualized stimulation target was located over the left dorsolateral prefrontal cortex using integrated neuronavigation, and the target coordinates were saved for subsequent sessions. Resting motor threshold was measured before treatment. Each daily session delivered 1,800 pulses in three blocks of 600 pulses. Stimulation consisted of three 50-Hz pulses repeated at 5 Hz in 2-second trains separated by 8-second intervals. Stimulation was delivered at 100% of the participant's resting motor threshold.
| Study group | Role | What they receive |
|---|---|---|
| Combined iACT and iTBS | Experimental | Participants received intermittent theta burst stimulation once daily for 12 consecutive days and completed six sequential internet-delivered Acceptance and Commitment Therapy modules on days 1, 3, 5, 7, 9, and 11. On module days, iTBS was administered immediately before the iACT module. Receives: Behavioral: Internet-Delivered Acceptance and Commitment Therapy; Device: Intermittent Theta Burst Stimulation |
| iACT Only | Experimental | Participants completed six sequential internet-delivered Acceptance and Commitment Therapy modules over 12 days, with modules delivered on days 1, 3, 5, 7, 9, and 11. Receives: Behavioral: Internet-Delivered Acceptance and Commitment Therapy |
| iTBS Only | Experimental | Participants received intermittent theta burst stimulation over the left dorsolateral prefrontal cortex once daily for 12 consecutive days. Receives: Device: Intermittent Theta Burst Stimulation |
| Waitlist Control | No intervention | Participants received no targeted study intervention during the 42-day study period and completed assessments at the same time points as the active intervention groups. Participants were offered access to the iACT program after the final follow-up assessment. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in subjective sleep quality measured by the Pittsburgh Sleep Quality Index (PSQI)
Subjective sleep quality will be assessed with the 19-item Pittsburgh Sleep Quality Index (PSQI). Total scores range from 0 to 21, with higher scores indicating poorer subjective sleep quality. The primary outcome is the change in PSQI total score from baseline to immediately after the 12-day intervention and from baseline to the 30-day follow-up. Negative change scores indicate improvement in subjective sleep quality.
Measured: Baseline to immediately postintervention (day 12) and baseline to 30-day follow-up (day 42)
Secondary outcomes (2)
Change in depressive symptom severity measured by the 17-item Hamilton Depression Rating Scale (HAMD-17)
Depressive symptom severity will be assessed with the 17-item Hamilton Depression Rating Scale (HAMD-17), a clinician-rated measure with scores ranging from 0 to 52. Higher scores indicate more severe depressive symptoms. The secondary outcome is the change in HAMD-17 score from baseline to immediately after the 12-day intervention and from baseline to the 30-day follow-up. Negative change scores indicate improvement in depressive symptoms.
Measured: Baseline to immediately postintervention (day 12) and baseline to 30-day follow-up (day 42)
Change in psychological flexibility measured by the Multidimensional Psychological Flexibility Inventory-24 (MPFI-24)
Psychological flexibility will be assessed using the 12-item flexibility subscale of the Multidimensional Psychological Flexibility Inventory-24 (MPFI-24). Scores range from 12 to 72, with higher scores indicating greater psychological flexibility. The secondary outcome is the change in the flexibility subscale score from baseline to immediately after the 12-day intervention and from baseline to the 30-day follow-up. Positive change scores indicate improvement in psychological flexibility.
Measured: Baseline to immediately postintervention (day 12) and baseline to 30-day follow-up (day 42)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Sep 2026
- Study start1 Aug 2023
- Primary completion1 Jan 2024
- Study completion30 Jan 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Depressive DisorderStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Investigator, Outcomes assessor
- Enrolment
- 160 participants (actual)
Sponsor and investigators
- Lead sponsor
- Central China Normal University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Zhihong Ren, Central China Normal University
- Investigators
- Zhihong Ren, PhD, Principal investigator, Central China Normal University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07807072
- Sponsor's protocol ID
- CCNU-IRB-202306017b
- Other IDs
- https://osf.io/8ewc
- Status last verified
- Sep 2026
- First submitted
- 2 Sep 2026
- Last updated
- 8 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be shared publicly because the study involves minors and sensitive psychiatric and health information. Data sharing is restricted by the informed consent process, institutional data-governance policies, and applicable ethics and privacy requirements. The consent obtained from participants and their legal guardians did not authorize unrestricted public release of individual-level data. De-identified aggregate results will be reported in publications and other appropriate research outputs.
Study at a glance
From the registry record, last updated by the sponsor on 8 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Internet-Delivered ACT and Intermittent Theta Burst Stimulation for Subjective Sleep Quality in Depressed Adolescents: A Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT07807072
- Acronym / sponsor ID
- CCNU-IRB-202306017b
- Conditions
- Depressive Disorder, Sleep Disturbance
- Keywords
- Subjective sleep quality, depression, internet-delivered Acceptance and Commitment Therapy, intermittent Theta Burst Stimulation, psychological flexibility
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 160 participants (actual)
- Lead sponsor
- Central China Normal UniversityUniversity, hospital or other
- Study start
- 1 Aug 2023 (actual)
- Primary completion
- 1 Jan 2024 (actual)
- Study completion
- 30 Jan 2024 (actual)
- First posted
- 8 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study evaluated whether combining an internet-delivered Acceptance and Commitment Therapy program with intermittent theta burst stimulation improves subjective sleep quality in adolescents with depressive disorders and sleep disturbances. Acceptance and Commitment Therapy is a psychological treatment that teaches skills for accepting difficult thoughts and feelings, reducing unhelpful struggle with them, and taking actions consistent with personal values. Intermittent theta burst stimulation is a brief, noninvasive form of brain stimulation delivered over the left dorsolateral prefrontal cortex.
A total of 152 adolescents aged 11 to 19 years were randomly assigned to one of four groups: combined internet-delivered Acceptance and Commitment Therapy plus intermittent theta burst stimulation, internet-delivered Acceptance and Commitment Therapy alone, intermittent theta burst stimulation alone, or a waitlist control group. Treatment was provided over 12 consecutive days. Participants completed assessments before treatment, immediately after treatment, and 30 days later.
The study was registered retrospectively after participant recruitment and data collection had begun. The primary outcome was subjective sleep quality, measured with the Pittsburgh Sleep Quality Index. Secondary outcomes were depressive symptom severity and psychological flexibility. The study also assessed treatment exposure and adverse events, including headache or scalp discomfort associated with brain stimulation.
Detailed description
This was a four-arm, parallel-group, randomized controlled superiority trial conducted in the outpatient department of a psychiatric hospital in Anhui Mental Health Center. The study was retrospectively registered on the Open Science Framework in May 2024. The study protocol was approved by the institutional review board (Approval No.: CCNU-IRB-202306017b). Written informed consent was obtained from a parent or legal guardian, and written assent was obtained from each adolescent participant.
Participants were recruited by convenience sampling between August 2023 and January 2024. Eligible participants were 11 to 19 years old; had a primary DSM-5 depressive disorder confirmed by independent evaluations from two board-certified psychiatrists using semistructured clinical interviews; had a Hamilton Depression Rating Scale, 17-item version (HAMD-17) score of at least 8; and reported a concurrent subjective sleep disturbance, such as difficulty initiating sleep, frequent nighttime awakenings, or nonrestorative sleep. Participants were required either to be receiving stable antidepressant pharmacotherapy for at least 2 weeks or to be taking no antidepressant medication. Participants could not be receiving another systematic psychological or physical treatment and were required to be right-handed.
Participants were excluded for a history of epilepsy, a major neurological disorder, a contraindication to transcranial magnetic stimulation, acute suicide risk, a substance use disorder within the preceding year, severe somatic illness, or current use of targeted hypnotic or sedative medication.
Participants were randomly assigned in a 1:1:1:1 ratio using a computer-generated permuted-block randomization sequence. Allocation was managed by personnel independent of outcome assessment. Independent HAMD-17 raters were masked to treatment assignment. Participants and intervention-delivery personnel were not masked because the treatment formats and waitlist condition were distinguishable. Self-report outcome measures were completed by participants.
The internet-delivered Acceptance and Commitment Therapy program was provided through a custom-developed WeChat mini-program. The program included an introduction, six sequential treatment modules, and a concluding session. The content was delivered over 12 days and covered psychoeducation, acceptance, cognitive defusion, mindfulness, values clarification, and values-consistent action. The modules were unlocked on days 1, 3, 5, 7, 9, and 11, with approximately 15 minutes required for each component. The total planned exposure was approximately 120 minutes. All modules were completed on site during daily hospital visits. Online records and staff monitoring were used to document module completion and practice activities. A crisis hotline was embedded in the program.
Intermittent theta burst stimulation was administered once daily for 12 consecutive days using a Magstim Rapid2 stimulator with a 70-mm figure-of-eight coil. The individualized stimulation target was located over the left dorsolateral prefrontal cortex using integrated neuronavigation. Resting motor threshold was measured before treatment. Each session delivered 1,800 pulses in three 600-pulse blocks. Stimulation consisted of three-pulse 50-Hz bursts repeated at 5 Hz, delivered in 2-second trains separated by 8-second intervals. Stimulation intensity was 100% of the participant's resting motor threshold.
Participants in the combined group received both interventions. On days when a new Acceptance and Commitment Therapy module was available, theta burst stimulation was delivered first and was immediately followed by the module. On intervening days, participants received theta burst stimulation only. Participants in the internet-delivered therapy-only group followed the module schedule without theta burst stimulation. Participants in the stimulation-only group received theta burst stimulation without the therapy program during the intervention period. Participants assigned to the waitlist received no targeted intervention during the 42-day study period and completed assessments on the same schedule as the active-treatment groups. Access to the internet-delivered Acceptance and Commitment Therapy program was offered to participants in the waitlist and stimulation-only groups after the final follow-up assessment.
Assessments were conducted at baseline, immediately after the 12-day intervention, and at a 30-day follow-up. The primary outcome was subjective sleep quality, measured with the 19-item Pittsburgh Sleep Quality Index, with total scores ranging from 0 to 21 and higher scores indicating worse sleep quality. Secondary outcomes were depressive symptom severity, measured with the 17-item Hamilton Depression Rating Scale, and psychological flexibility, measured with the 12-item flexibility subscale of the Multidimensional Psychological Flexibility Inventory-24. Demographic information, including age, gender, school grade, only-child status, and urban or rural residence, was collected at baseline.
Adverse events and unintended effects were assessed through spontaneous participant reports during and after the intervention procedures. Examples included headache and scalp discomfort associated with intermittent theta burst stimulation.
The primary analyses examined changes from baseline to post-treatment and follow-up across the four groups. Repeated-measures models were used to account for the correlation among observations from the same participant. The main comparisons evaluated the combined intervention against the waitlist and against each monotherapy, as well as each monotherapy against the waitlist. Analyses adjusted for age, gender, and only-child status. Additional analyses examined clinical response in sleep quality, the robustness of findings under alternative model specifications, and whether the combined intervention showed evidence of greater-than-additive change relative to the two monotherapies. All 152 participants completed the three scheduled assessments.
This study was registered retrospectively after participant recruitment and data collection had begun.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (investigator, outcomes assessor)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Combined iACT and iTBS | Experimental | Behavioral: Internet-Delivered Acceptance and Commitment Therapy, Device: Intermittent Theta Burst StimulationParticipants received intermittent theta burst stimulation once daily for 12 consecutive days and completed six sequential internet-delivered Acceptance and Commitment Therapy modules on days 1, 3, 5, 7, 9, and 11. On module days, iTBS was administered immediately before the iACT module. |
| iACT Only | Experimental | Behavioral: Internet-Delivered Acceptance and Commitment TherapyParticipants completed six sequential internet-delivered Acceptance and Commitment Therapy modules over 12 days, with modules delivered on days 1, 3, 5, 7, 9, and 11. |
| iTBS Only | Experimental | Device: Intermittent Theta Burst StimulationParticipants received intermittent theta burst stimulation over the left dorsolateral prefrontal cortex once daily for 12 consecutive days. |
| Waitlist Control | No intervention | –Participants received no targeted study intervention during the 42-day study period and completed assessments at the same time points as the active intervention groups. Participants were offered access to the iACT program after the final follow-up assessment. |
Who may qualify
- Ages
- 11 to 19 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
Key inclusion criteria (8 listed)
- Age 11 to 19 years.
- A primary depressive disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), confirmed by independent evaluations conducted by two board-certified psychiatrists using semistructured clinical interviews. Any discrepancy was adjudicated by a senior psychiatrist.
- Hamilton Depression Rating Scale, 17-item version (HAMD-17) score of at least 8.
- Current subjective sleep disturbance, including difficulty initiating sleep, frequent nighttime awakenings, or nonrestorative sleep, confirmed during the diagnostic interview.
- Either no antidepressant medication or stable antidepressant pharmacotherapy for at least 2 weeks before enrollment.
Key exclusion criteria (5 listed)
- History of epilepsy, major neurological disorder, or any contraindication to transcranial magnetic stimulation, including relevant metal implants.
- Acute suicide risk requiring immediate clinical intervention.
- Substance use disorder within the previous year.
- Severe somatic illness that could interfere with study participation or outcome assessment.
- Current use of targeted hypnotic or sedative medication.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Internet-Delivered Acceptance and Commitment TherapyAlso: iACT, Internet-delivered ACTParticipants received a self-guided internet-delivered Acceptance and Commitment Therapy program through a custom-developed WeChat mini-program over 12 consecutive days. The program included an introduction, six sequential treatment modules, and a concluding session. Modules were unlocked on days 1, 3, 5, 7, 9, and 11, and each component required approximately 15 minutes, for a total planned exposure of approximately 120 minutes. Content was based on the ACT hexaflex model and included psychoeducation, acceptance, cognitive defusion, mindfulness, values clarification, and values-consistent action. Participants completed the modules on site during daily hospital visits. Module completion and practice activities were monitored through the mini-program and by research staff. A crisis hotline was embedded in the program. | Behavioural | Combined iACT and iTBS, iACT Only |
| Intermittent Theta Burst StimulationAlso: iTBS, Intermittent TBSIntermittent theta burst stimulation was administered once daily for 12 consecutive days using a Magstim Rapid2 stimulator with a 70-mm figure-of-eight coil. The individualized stimulation target was located over the left dorsolateral prefrontal cortex using integrated neuronavigation, and the target coordinates were saved for subsequent sessions. Resting motor threshold was measured before treatment. Each daily session delivered 1,800 pulses in three blocks of 600 pulses. Stimulation consisted of three 50-Hz pulses repeated at 5 Hz in 2-second trains separated by 8-second intervals. Stimulation was delivered at 100% of the participant's resting motor threshold. | Device | Combined iACT and iTBS, iTBS Only |
Primary outcome
Change in subjective sleep quality measured by the Pittsburgh Sleep Quality Index (PSQI)
Time frame: Baseline to immediately postintervention (day 12) and baseline to 30-day follow-up (day 42)
Subjective sleep quality will be assessed with the 19-item Pittsburgh Sleep Quality Index (PSQI). Total scores range from 0 to 21, with higher scores indicating poorer subjective sleep quality. The primary outcome is the change in PSQI total score from baseline to immediately after the 12-day intervention and from baseline to the 30-day follow-up. Negative change scores indicate improvement in subjective sleep quality.
2 secondary outcomes
Change in depressive symptom severity measured by the 17-item Hamilton Depression Rating Scale (HAMD-17)
Time frame: Baseline to immediately postintervention (day 12) and baseline to 30-day follow-up (day 42)
Change in psychological flexibility measured by the Multidimensional Psychological Flexibility Inventory-24 (MPFI-24)
Time frame: Baseline to immediately postintervention (day 12) and baseline to 30-day follow-up (day 42)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Sep 2026.
- Individual participant dataSharing planned: No. Individual participant data will not be shared publicly because the study involves minors and sensitive psychiatric and health information. Data sharing is restricted by the informed consent process, institutional data-governance policies, and applicable ethics and privacy requirements. The consent obtained from participants and their legal guardians did not authorize unrestricted public release of individual-level data. De-identified aggregate results will be reported in publications and other appropriate research outputs.
Related trials for Depressive Disorder
Recruiting
Unified Protocol in Penitentiary Facilities
Depression Disorders, Anxiety
Not yet recruiting
Preventive and Personalized Digital Emotion Regulation Skills Intervention to Reduce Depression and Anxiety in Youths With Adverse Childhood Experiences
Adverse Childhood Experience, Depression / Major Depressive Disorder
Not yet recruitingObservational study
Functional Impact of Psychological Symptoms in Patients With Superior Semicircular Canal Dehiscence Syndrome (SSCD): a National Cross-sectional Study
Superior Semicircular Canal Dehiscence
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
Recruiting
Cultural Adaptation of an Online Parenting Intervention to Reduce the Risk of Depression and Anxiety in Adolescents
Risk of Depression and Anxiety
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Zhihong Ren, PhD principal investigator
Central China Normal University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Internet-Delivered Acceptance and Commitment Therapy and Intermittent Theta Burst Stimulation in people with Depressive Disorder and Sleep Disturbance, run by Central China Normal University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in subjective sleep quality measured by the Pittsburgh Sleep Quality Index (PSQI) (time frame: Baseline to immediately postintervention (day 12) and baseline to 30-day follow-up (day 42)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Sep 2026.